1872-P: Initiation of Omnipod 5 Automated Insulin Delivery System among Individuals with Type 2 Diabetes and Acute Glycemic Events Requiring Emergency Department and Inpatient Hospital Care

Introduction and Objective: AID systems have recently received regulatory approval in the US for T2D. Given the recent indication, data on the efficacy of AID in reducing acute glycemic events is limited. The objective of this analysis was to estimate the association between Omnipod 5 initiation and emergency care utilization for acute glycemic events in people with T2D. Methods: We conducted a retrospective cohort study using claims data via the Komodo Research Database. The analysis included people with T2D who filled a prescription for Omnipod 5 between 8/1/2022 and 8/1/2024 and refilled within 180 days. The endpoints were utilization of emergency department (ED) or hospital care with a primary diagnosis code relating to hyperglycemia or hypoglycemia, specified as binary and count outcomes. We used descriptive statistics and generalized estimating equations (GEE) to assess care utilization one year pre-/post-Omnipod 5 initiation. GEEs used logit and poisson link functions and exchangeable correlation structure to adjust for covariates, including age, sex, payer type, and CGM use, among others. Results: Among the 26,171 individuals who met the inclusion criteria, ED utilization and inpatient care for hyperglycemia-related causes decreased with Omnipod 5 use, with minimal differences in hypoglycemia-related care, which was extremely rare in both time periods. After adjusting for covariates, the odds of requiring an ED visit or inpatient care for hyperglycemia were 0.72 and 0.59, respectively, relative to pre-initiation (p<0.001). Similarly, the incidence rate ratios for ED visits, inpatient admissions, and nights spent hospitalized were 0.76, 0.63, and 0.60 (all p<0.001), respectively, relative to baseline. Conclusion: Omnipod 5 is associated with notable reductions in ED and hospital care utilization for hyperglycemic events among initiators with T2D, with no accompanying increase in hypoglycemic events requiring care. Disclosure J. Weinstein: Employee; Current; Insulet Corporation. D. Carlow: Employee; Current; Insulet Corporation. Stock/Shareholder; Current; Insulet Corporation, Dexcom, Inc.